Molecular pathogenesis of malignant melanoma: A different perspective from the studies of melanocytic nevus and acral melanoma

Pigment Cell and Melanoma Research

Volumn 23, Issue 1, 2010, Pages 64-71

  Takata, Minoru ^a   Murata, Hiroshi ^a   Saida, Toshiaki ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acral melanoma; Gene amplification; Melanocytic nevus; Mucosal melanoma; Oncogene mutation

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; STEM CELL FACTOR;

ACRAL MELANOMA; CANCER STAGING; CAUCASIAN; DISEASE COURSE; EPIDERMIS; GENE AMPLIFICATION; GENE MUTATION; GENETIC MODEL; HUMAN; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MOLECULAR GENETICS; MUCOSAL DISEASE; MUTATION; PATHOGENESIS; PREVALENCE; REVIEW; SKIN DEFECT; SUN;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MUTATION; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 74349114086     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00645.x     Document Type: Review

References (53)

1. Ackerman, A.B. (1980). Malignant melanoma: a unifying concept. Hum. Pathol. 11, 591 595.
2. Ackerman, A.B. Mihara, I. (1985). Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas. Hum. Pathol. 16, 87 91.
3. Antonescu, C.R., Busam, K.J., Francone, T.D. et al. (2007). L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121, 257 264.
4. Ashida, A., Takata, M., Murata, H., Kido, K. Saida, T. (2009). Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer 124, 862 868.
5. Balch, C.M., Buzaid, A.C., Atkins, M.B. et al. (2000). A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88, 1484 1491.
6. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A.F., Zeuthen, J. Bartek, J. (1996). The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56, 5475 5483.
7. Bastian, B.C. (2003). Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 22, 3081 3086.
8. Bastian, B.C., Kashani-Sabet, M., Hamm, H., Godfrey, T., Moore, 2nd. D.H., Brocker, E.B., LeBoit, P.E. Pinkel, D. (2000). Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60, 1968 1973.
9. Beadling, C., Jacobson-Dunlop, E., Hodi, F.S. et al. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821 6828.
10. Bennett, D.C. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063 3069.
11. Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27 38.
12. Clark Jr., W.H., Reimer, R.R., Greene, M., Ainsworth, A.M. Mastrangelo, M.J. (1978). Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch. Dermatol. 114, 732 738.
13. Clark Jr., W.H., Goldman, L.I. Mastrangelo, M.J. (1979). Human malignant melanoma. New York (USA) : Grune & Stratton.
14. Clark Jr., W.H., Elder, D.E., Guerry, D.t., Epstein, M.N., Greene, M.H. Van Horn, M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 1147 1165.
15. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135 2147.
16. Curtin, J.A., Busam, K., Pinkel, D. Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340 4346.
17. Dash, B.C. El-Deiry, W.S. (2004). Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol. Biol. 280, 99 161.
18. Dhomen, N., Reis-Filho, J.S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C. Marais, R. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294 303.
19. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D. Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496 505.
20. Hodi, F.S., Friedlander, P., Corless, C.L. et al. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046 2051.
21. Hussussian, C.J., Struewing, J.P., Goldstein, A.M., Higgins, P.A., Ally, D.S., Sheahan, M.D., Clark Jr., W.H., Tucker, M.A. Dracopoli, N.C. (1994). Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15 21.
22. Ichii-Nakato, N., Takata, M., Takayanagi, S., Takashima, S., Lin, J., Murata, H., Fujimoto, A., Hatta, N. Saida, T. (2006). High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J. Invest. Dermatol. 126, 2111 2118.
23. Imokawa, G., Yada, Y. Miyagishi, M. (1992). Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J. Biol. Chem. 267, 24675 24680.
24. Jiang, X., Zhou, J., Yuen, N.K. et al. (2008). Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 7726 7732.
25. LeBoit, P.E., Burg, G., Weedon, D. Sarasin, A. (2006). Skin tumours. Pathology and genetics. Lyon (France) : IARCPress.
26. Lee, J.Y., Dong, S.M., Shin, M.S. et al. (1997). Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem. Biophys. Res. Commun. 237, 667 672.
27. Li, G., Satyamoorthy, K., Meier, F., Berking, C., Bogenrieder, T. Herlyn, M. (2003). Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22, 3162 3171.
28. Lin, J., Takata, M., Murata, H., Goto, Y., Kido, K., Ferrone, S. Saida, T. (2009). Polyclonality of BRAF mutations in acquired melanocytic nevi. J. Natl Cancer Inst, DOI :.
29. Lutzky, J., Bauer, J. Bastian, B.C. (2008). Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res., 21, 492 493.
30. Maldonado, J.L., Fridlyand, J., Patel, H. et al. (2003). Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 1878 1890.
31. Michaloglou, C., Vredeveld, L.C., Soengas, M.S. et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720 724.
32. Michaloglou, C., Vredeveld, L.C., Mooi, W.J. Peeper, D.S. (2008). BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877 895.
33. Miller, A.J. Mihm Jr., M.C. (2006). Melanoma. N. Engl. J. Med. 355, 51 65.
34. Montone, K.T., van Belle, P., Elenitsas, R. Elder, D.E. (1997). Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod. Pathol. 10, 939 944.
35. Murata, H., Ashida, A., Takata, M., Yamaura, M., Bastian, B.C. Saida, T. (2007). Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. Cancer Sci. 98, 958 963.
36. Natali, P.G., Nicotra, M.R., Winkler, A.B., Cavaliere, R., Bigotti, A. Ullrich, A. (1992). Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int. J. Cancer 52, 197 201.
37. North, J.P., Kageshita, T., Pinkel, D., Leboit, P.E. Bastian, B.C. (2008). Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J. Invest. Dermatol. 128, 2024 2030.
38. Patnaik, M.M., Tefferi, A. Pardanani, A. (2007). Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 7, 492 503.
39. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19 20.
40. Polsky, D., Young, A.Z., Busam, K.J. Alani, R.M. (2001). The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res. 61, 6008 6011.
41. Reed, J.A., Loganzo Jr., F., Shea, C.R. et al. (1995). Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 55, 2713 2718.
42. Rivera, R.S., Nagatsuka, H., Gunduz, M. et al. (2008). C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 452, 27 32.
43. Rivers, J.K. (2004). Is there more than one road to melanoma? Lancet 363, 728 730.
44. Saida, T. (1994). The concept of de novo origin of cutaneous malignant melanoma. Eur J Dermatol 4, 252 254.
45. Sauter, E.R., Yeo, U.C., von Stemm, A. et al. (2002). Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62, 3200 3206.
46. Sviderskaya, E.V., Hill, S.P., Evans-Whipp, T.J. et al. (2002). p16(Ink4a) in melanocyte senescence and differentiation. J. Natl Cancer Inst. 94, 446 454.
47. Sviderskaya, E.V., Gray-Schopfer, V.C., Hill, S.P. et al. (2003). p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl Cancer Inst. 95, 723 732.
48. Takata, M., Goto, Y., Ichii, N., Yamaura, M., Murata, H., Koga, H., Fujimoto, A. Saida, T. (2005). Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J. Invest. Dermatol. 125, 318 322.
49. Tashiro, E., Tsuchiya, A. Imoto, M. (2007). Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98, 629 635.
50. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D. Bastian, B.C. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5, e120.
51. Wehrle-Haller, B. (2003). The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 16, 287 296.
52. Willmore-Payne, C., Holden, J.A., Hirschowitz, S. Layfield, L.J. (2006). BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum. Pathol. 37, 520 527.
53. Yamaura, M., Takata, M., Miyazaki, A. Saida, T. (2005). Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ. Arch. Dermatol. 141, 1413 1418.